Evotec Announces Phase I Initiation with P2X7 Antagonist

Date Posted: Friday, October 10, 2008

Print Email to a friend

Evotec AG has announced that Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist have been initiated.

The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines. P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions, which affect millions of individuals.

The first Phase I study is a double-blind and placebo-controlled single ascending dose study in healthy male volunteers to evaluate the compound’s safety, tolerability, pharmacokinetic profile and pharmacodynamic effects after oral administration.

Further Information: http://www.evotec.com



Related news from our archive

Evotec Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study
The Phase II proof-of-concept study will investigate the effect of EVT 302 on the quit rate of patients who want to stop smoking.

Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer
The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study in healthy volunteers.

Evotec’s EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
The study showed in both young and elderly subjects that EVT 101 was well tolerated up to the highest dose tested.